Tag: standard

TORONTO, July 11, 2025 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) today announced the commencement of separate offers (the “Offers”) to purchase for cash up to C$400,000,000 (the “Maximum Purchase Amount”) in aggregate purchase price, excluding accrued and unpaid interest, of its outstanding senior notes of each series listed in the table below (collectively, the “Notes”), which Maximum Purchase Amount may be increased, decreased or waived by the Company in its sole discretion. Each Offer is subject to the satisfaction or waiver of certain conditions.

Exhale Wellness launches Bottle Caps Delta 9 Gummies in retro soda flavors. Each gummy blends nostalgic taste with a reliable, plant-based formula.

Jerusalem and Milan, July 11, 2025 (8:30 AM CET) – Solargik, a global pioneer in photovoltaic terrain-adaptive energy solutions today announced the signing of 85 megawatts (MW) in new utility-scale solar projects across Italy, marking a significant step in opening up solar deployment in areas long considered too steep, constrained, or regulated for viable installation in Europe.

Gerusalemme e Milano, 11 luglio 2025 (08:30 CET) – Solargik, pioniere mondiale nelle soluzioni fotovoltaiche adattive al terreno, ha annunciato oggi la firma di nuovi progetti solari su scala utility per un totale di 85 megawatt (MW) in tutta Italia, segnando un passo significativo nell’apertura del fotovoltaico in aree da tempo considerate troppo scoscese, vincolate o regolamentate per un’installazione fotovoltaica sostenibile in Europa.

BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single compassionate use, Investigational New Drug (“IND”) authorization cleared by the U.S. Food and Drug Administration (“FDA”), to a patient with mild-stage Alzheimer’s disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab, an amyloid targeting therapy. This exploratory work is being conducted in collaboration with Anita Fletcher, M.D., a board-certified neurologist with specialized training in neuroimmunology, who also serves as Director of Neuroscience Clinical Research at AdventHealth Neuroscience Institute in Orlando, Florida.